A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis

Immunobiology

Volumn 222, Issue 3, 2017, Pages 544-551

  Ilan, Yaron ^a   Gingis Velitski, Svetlana ^b   Ben Ya'aco, Ami ^a   Shabbat, Yehudit ^a   Zolotarov, Lidya ^a   Almon, Einat ^b   Shaaltiel, Yoseph ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Protalix Biotherapeutics   (Israel)

Author keywords

Anti TNF fusion protein; Colitis; Immune mediated hepatitis; Oral tolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; IMMUNOMODULATING AGENT; PRX 106; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; HYBRID PROTEIN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FLUORESCENCE ACTIVATED CELL SORTING; HISTOLOGY; IMMUNE MEDIATED COLITIS; IMMUNE MEDIATED HEPATITIS; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOPSY; BLOOD; COLITIS; DISEASE MODEL; DRUG EFFECTS; HEPATITIS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PLANT CELL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOPSY; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HEPATITIS; INTESTINAL MUCOSA; MALE; MICE; PLANT CELLS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006292572     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2016.11.001     Document Type: Article

References (48)

1. Ahmad, K., Rogers, S., Development of Crohn disease in a patient on etanercept for psoriasis. Br. J. Dermatol., 157, 2007, 396.
2. Aversa, G., Punnonen, J., de Vries JE. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J. Exp. Med. 177 (1993), 1575–1585.
3. Bendtzen, K., Ainsworth, M., Steenholdt, C., et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand. J. Gastroenterol. 44 (2009), 774–781.
4. Biton, J., Semerano, L., Delavallee, L., et al. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J. Immunol. 186 (2011), 3899–3910.
5. Calleja, S., Cordero-Coma, M., Rodriguez, E., et al. Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(−) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond.) 26 (2012), 468–477.
6. Cassani, B., Villablanca, E.J., Quintana, F.J., et al. Gut-tropic T cells that express integrin alpha4beta7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology 141 (2011), 2109–2118.
7. Castro-Sanchez, P., Martin-Villa, J.M., Gut immune system and oral tolerance. Br. J. Nutr. 109:Suppl. 2 (2013), S3–11.
8. Di Sabatino, A., Ciccocioppo, R., Cinque, B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004), 70–77.
9. Dubeau, M.F., Iacucci, M., Beck, P.L., et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm. Bowel Dis. 19 (2013), 445–456.
10. Evans, T.J., Moyes, D., Carpenter, A., et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 180 (1994), 2173–2179.
11. Falcone, M., Facciotti, F., Ghidoli, N., et al. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 172 (2004), 5908–5916.
12. Gils, M., Kandzia, R., Marillonnet, S., et al. High-yield production of authentic human growth hormone using a plant virus-based expression system. Plant Biotechnol. J. 3 (2005), 613–620.
13. Haider, A.S., Cardinale, I.R., Whynot, J.A., et al. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J. Invest. Dermatol. Symp. Proc. 12 (2007), 9–15.
14. Haraoui, B., Krelenbaum, M., Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin. Arthritis Rheum. 39 (2009), 176–181.
15. Hoy, S.M., Scott, L.J., Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis. Drugs 67 (2007), 2609–2633.
16. Huang, Z., Yang, B., Shi, Y., et al. Anti-TNF-alpha therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell. Immunol. 279 (2012), 25–29.
17. Ilan, Y., Maron, R., Tukpah, A.M., et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 9765–9770.
18. Ilan, Y., Zigmond, E., Lalazar, G., et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J. Clin. Immunol. 30 (2010), 167–177.
19. Ilan, Y., Oral tolerance: can we make it work. Hum. Immunol. 70 (2009), 768–776.
20. Ilan, Y., Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease. Clin. Transl. Immunol., 5, 2016, e60.
21. Ilan, Y., Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 310 (2016), G1102–17.
22. Ishikawa, H., Ochi, H., Chen, M.L., et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56 (2007), 2103–2109.
23. Israeli, E., Ilan, Y., Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease. Ther. Adv. Gastroenterol. 3 (2010), 23–30.
24. Kinkhabwala, M., Sehajpal, P., Skolnik, E., et al. A novel addition to the T cell repertory: cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J. Exp. Med. 171 (1990), 941–946.
25. Lamb, J.A., Ventura, J.J., Hess, P., et al. JunD mediates survival signaling by the JNK signal transduction pathway. Mol. Cell 11 (2003), 1479–1489.
26. Lerner, I., Hermano, E., Zcharia, E., et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 121 (2011), 1709–1721.
27. Margalit, M., Ghazala, S.A., Alper, R., et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005), G917–25.
28. Miehsler, W., Novacek, G., Wenzl, H., et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J. Crohns Colitis 4 (2010), 221–256.
29. Mizrahi, M., Ilan, Y., The gut mucosa as a site for induction of regulatory T-cells. Curr. Pharm. Des. 15 (2009), 1191–1202.
30. Mudter, J., Neurath, M.F., Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 56 (2007), 293–303.
31. Nadkarni, S., Mauri, C., Ehrenstein, M.R., Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 204 (2007), 33–39.
32. Ochi, H., Abraham, M., Ishikawa, H., et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J. Neurol. Sci. 274 (2008), 9–12.
33. Pang, L., Wang, L., Suo, T., et al. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis. J. Rheumatol. 35 (2008), 2220–2228.
34. Peron, J.P., Yang, K., Chen, M.L., et al. Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice. J. Neuroimmunol. 227 (2010), 10–17.
35. Rahimi, R., Nikfar, S., Abdollahi, M., Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? a systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother. 61 (2007), 75–80.
36. Requena, P., Gonzalez, R., Lopez-Posadas, R., et al. The intestinal antiinflammatory agent glycomacropeptide has immunomodulatory actions on rat splenocytes. Biochem. Pharmacol. 79 (2010), 1797–1804.
37. Rongioletti, F., Burlando, M., Parodi, A., Adverse effects of biological agents in the treatment of psoriasis. Am. J. Clin. Dermatol. 11:Suppl. 1 (2010), 35–37.
38. Sandborn, W.J., Hanauer, S.B., Katz, S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001), 1088–1094.
39. Stallmach, A., Hagel, S., Bruns, T., Adverse effects of biologics used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24 (2010), 167–182.
40. Sugita, S., Yamada, Y., Kaneko, S., et al. Induction of regulatory T cells by infliximab in Behcet's disease. Invest. Ophthalmol. Vis. Sci. 52 (2011), 476–484.
41. Travers, S.B., Etanercept for crohn's disease. N. Engl. J. Med., 350, 2004, 840 author rely 840.
42. Van den Brande, J.M., Braat, H., van den Brink, G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003), 1774–1785.
43. Varfolomeev, E.E., Ashkenazi, A., Tumor necrosis factor: an apoptosis JuNKie. Cell 116 (2004), 491–497.
44. Weiner, H.L., da Cunha, A.P., Quintana, F., et al. Oral tolerance. Immunol. Rev. 241 (2011), 241–259.
45. Wiedmann, M.W., Mossner, J., Baerwald, C., et al. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr. Metab. Immune Disord. Drug Targets 9 (2009), 295–314.
46. Wu, H.Y., Maron, R., Tukpah, A.M., et al. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J. Immunol. 185 (2010), 3401–3407.
47. da Cunha, A.P., Weiner, H.L., Induction of immunological tolerance by oral anti-CD3. Clin. Dev. Immunol., 2012, 2012, 425021.
48. ten Hove, T., van Montfrans, C., Peppelenbosch, M.P., et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002), 206–211.